261 related articles for article (PubMed ID: 21978836)
21. New developments in non-quinolone-based antibiotics for the inhibiton of bacterial gyrase and topoisomerase IV.
Badshah SL; Ullah A
Eur J Med Chem; 2018 May; 152():393-400. PubMed ID: 29751233
[TBL] [Abstract][Full Text] [Related]
22. Novel topoisomerase inhibitors: microbiological characterisation and in vivo efficacy of pyrimidines.
Uria-Nickelsen M; Neckermann G; Sriram S; Andrews B; Manchester JI; Carcanague D; Stokes S; Hull KG
Int J Antimicrob Agents; 2013 Apr; 41(4):363-71. PubMed ID: 23305654
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and antibacterial activity of novel and potent DNA gyrase inhibitors with azole ring.
Tanitame A; Oyamada Y; Ofuji K; Fujimoto M; Suzuki K; Ueda T; Terauchi H; Kawasaki M; Nagai K; Wachi M; Yamagishi J
Bioorg Med Chem; 2004 Nov; 12(21):5515-24. PubMed ID: 15465328
[TBL] [Abstract][Full Text] [Related]
24. DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: synthesis and antibacterial activity.
East SP; White CB; Barker O; Barker S; Bennett J; Brown D; Boyd EA; Brennan C; Chowdhury C; Collins I; Convers-Reignier E; Dymock BW; Fletcher R; Haydon DJ; Gardiner M; Hatcher S; Ingram P; Lancett P; Mortenson P; Papadopoulos K; Smee C; Thomaides-Brears HB; Tye H; Workman J; Czaplewski LG
Bioorg Med Chem Lett; 2009 Feb; 19(3):894-9. PubMed ID: 19095445
[TBL] [Abstract][Full Text] [Related]
25. Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
Ho SY; Wang W; Ng FM; Wong YX; Poh ZY; Tan SWE; Ang SH; Liew SS; Joyner Wong YS; Tan Y; Poulsen A; Pendharkar V; Sangthongpitag K; Manchester J; Basarab G; Hill J; Keller TH; Cherian J
Eur J Med Chem; 2018 Sep; 157():610-621. PubMed ID: 30125722
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and structure-activity relationship studies of novel indazole analogues as DNA gyrase inhibitors with Gram-positive antibacterial activity.
Tanitame A; Oyamada Y; Ofuji K; Kyoya Y; Suzuki K; Ito H; Kawasaki M; Nagai K; Wachi M; Yamagishi J
Bioorg Med Chem Lett; 2004 Jun; 14(11):2857-62. PubMed ID: 15125947
[TBL] [Abstract][Full Text] [Related]
27. Synthesis, cytotoxicity and antimicrobial activity of thiourea derivatives incorporating 3-(trifluoromethyl)phenyl moiety.
Bielenica A; Stefańska J; Stępień K; Napiórkowska A; Augustynowicz-Kopeć E; Sanna G; Madeddu S; Boi S; Giliberti G; Wrzosek M; Struga M
Eur J Med Chem; 2015 Aug; 101():111-25. PubMed ID: 26119992
[TBL] [Abstract][Full Text] [Related]
28. Tyrosyl-tRNA synthetase inhibitors as antibacterial agents: synthesis, molecular docking and structure-activity relationship analysis of 3-aryl-4-arylaminofuran-2(5H)-ones.
Xiao ZP; Ma TW; Liao ML; Feng YT; Peng XC; Li JL; Li ZP; Wu Y; Luo Q; Deng Y; Liang X; Zhu HL
Eur J Med Chem; 2011 Oct; 46(10):4904-14. PubMed ID: 21856050
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and Evaluation of N-Phenylpyrrolamides as DNA Gyrase B Inhibitors.
Durcik M; Tammela P; Barančoková M; Tomašič T; Ilaš J; Kikelj D; Zidar N
ChemMedChem; 2018 Jan; 13(2):186-198. PubMed ID: 29206345
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and antibacterial activity of fluoroquinolones containing bulky arenesulfonyl fragment: 2D-QSAR and docking study.
Abdel-Aziz AA; Asiri YA; Al-Agamy MH
Eur J Med Chem; 2011 Nov; 46(11):5487-97. PubMed ID: 21982337
[TBL] [Abstract][Full Text] [Related]
31. Dual inhibition of Staphylococcus aureus DNA gyrase and topoisomerase IV activity by phenylalanine-derived (Z)-5-arylmethylidene rhodanines.
Werner MM; Patel BA; Talele TT; Ashby CR; Li Z; Zauhar RJ
Bioorg Med Chem; 2015 Sep; 23(18):6125-37. PubMed ID: 26320664
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of DNA gyrase and DNA topoisomerase IV of Staphylococcus aureus and Escherichia coli by aminocoumarin antibiotics.
Alt S; Mitchenall LA; Maxwell A; Heide L
J Antimicrob Chemother; 2011 Sep; 66(9):2061-9. PubMed ID: 21693461
[TBL] [Abstract][Full Text] [Related]
33. Hydroxy tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of RHS moiety (Part-3).
Singh SB; Kaelin DE; Wu J; Miesel L; Tan CM; Gill C; Black T; Nargund R; Meinke PT; Olsen DB; Lagrutta A; Wei C; Peng X; Wang X; Fukuda H; Kishii R; Takei M; Takeuchi T; Shibue T; Ohata K; Takano H; Ban S; Nishimura A; Fukuda Y
Bioorg Med Chem Lett; 2015 Jun; 25(12):2473-8. PubMed ID: 25978963
[TBL] [Abstract][Full Text] [Related]
34. Virtual Screening Approach and Investigation of Structure-Activity Relationships To Discover Novel Bacterial Topoisomerase Inhibitors Targeting Gram-Positive and Gram-Negative Pathogens.
Magarò G; Prati F; Garofalo B; Corso G; Furlotti G; Apicella C; Mangano G; D'Atanasio N; Robinson D; Di Giorgio FP; Ombrato R
J Med Chem; 2019 Aug; 62(16):7445-7472. PubMed ID: 31276392
[TBL] [Abstract][Full Text] [Related]
35. Structure-activity relationships of 3-aminoquinazolinediones, a new class of bacterial type-2 topoisomerase (DNA gyrase and topo IV) inhibitors.
Tran TP; Ellsworth EL; Sanchez JP; Watson BM; Stier MA; Showalter HD; Domagala JM; Shapiro MA; Joannides ET; Gracheck SJ; Nguyen DQ; Bird P; Yip J; Sharadendu A; Ha C; Ramezani S; Wu X; Singh R
Bioorg Med Chem Lett; 2007 Mar; 17(5):1312-20. PubMed ID: 17196390
[TBL] [Abstract][Full Text] [Related]
36. Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II: broad-spectrum antibacterial agents with reduced hERG activity.
Reck F; Alm R; Brassil P; Newman J; Dejonge B; Eyermann CJ; Breault G; Breen J; Comita-Prevoir J; Cronin M; Davis H; Ehmann D; Galullo V; Geng B; Grebe T; Morningstar M; Walker P; Hayter B; Fisher S
J Med Chem; 2011 Nov; 54(22):7834-47. PubMed ID: 21999508
[TBL] [Abstract][Full Text] [Related]
37. New dual ATP-competitive inhibitors of bacterial DNA gyrase and topoisomerase IV active against ESKAPE pathogens.
Durcik M; Nyerges Á; Skok Ž; Skledar DG; Trontelj J; Zidar N; Ilaš J; Zega A; Cruz CD; Tammela P; Welin M; Kimbung YR; Focht D; Benek O; Révész T; Draskovits G; Szili PÉ; Daruka L; Pál C; Kikelj D; Mašič LP; Tomašič T
Eur J Med Chem; 2021 Mar; 213():113200. PubMed ID: 33524686
[TBL] [Abstract][Full Text] [Related]
38. Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases.
Stokes NR; Thomaides-Brears HB; Barker S; Bennett JM; Berry J; Collins I; Czaplewski LG; Gamble V; Lancett P; Logan A; Lunniss CJ; Peasley H; Pommier S; Price D; Smee C; Haydon DJ
Antimicrob Agents Chemother; 2013 Dec; 57(12):5977-86. PubMed ID: 24041906
[TBL] [Abstract][Full Text] [Related]
39. Discovery of a novel azaindole class of antibacterial agents targeting the ATPase domains of DNA gyrase and Topoisomerase IV.
Manchester JI; Dussault DD; Rose JA; Boriack-Sjodin PA; Uria-Nickelsen M; Ioannidis G; Bist S; Fleming P; Hull KG
Bioorg Med Chem Lett; 2012 Aug; 22(15):5150-6. PubMed ID: 22814212
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and antibacterial activity of a novel series of DNA gyrase inhibitors: 5-[(E)-2-arylvinyl]pyrazoles.
Tanitame A; Oyamada Y; Ofuji K; Terauchi H; Kawasaki M; Wachi M; Yamagishi J
Bioorg Med Chem Lett; 2005 Oct; 15(19):4299-303. PubMed ID: 16087337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
